Cargando…
Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359976/ https://www.ncbi.nlm.nih.gov/pubmed/17519904 http://dx.doi.org/10.1038/sj.bjc.6603807 |
| _version_ | 1782152933357387776 |
|---|---|
| author | Karamouzis, M V Konstantinopoulos, P A Papavassiliou, A G |
| author_facet | Karamouzis, M V Konstantinopoulos, P A Papavassiliou, A G |
| author_sort | Karamouzis, M V |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2359976 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2007 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23599762009-09-10 Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics Karamouzis, M V Konstantinopoulos, P A Papavassiliou, A G Br J Cancer Letter to the Editor Nature Publishing Group 2007-06-18 2007-05-22 /pmc/articles/PMC2359976/ /pubmed/17519904 http://dx.doi.org/10.1038/sj.bjc.6603807 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Karamouzis, M V Konstantinopoulos, P A Papavassiliou, A G Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title | Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title_full | Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title_fullStr | Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title_full_unstemmed | Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title_short | Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics |
| title_sort | compartmentalisation of egfr signalling might potentiate the optimal use of egfr tyrosine kinase inhibitors in cancer therapeutics |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359976/ https://www.ncbi.nlm.nih.gov/pubmed/17519904 http://dx.doi.org/10.1038/sj.bjc.6603807 |
| work_keys_str_mv | AT karamouzismv compartmentalisationofegfrsignallingmightpotentiatetheoptimaluseofegfrtyrosinekinaseinhibitorsincancertherapeutics AT konstantinopoulospa compartmentalisationofegfrsignallingmightpotentiatetheoptimaluseofegfrtyrosinekinaseinhibitorsincancertherapeutics AT papavassiliouag compartmentalisationofegfrsignallingmightpotentiatetheoptimaluseofegfrtyrosinekinaseinhibitorsincancertherapeutics |